2020-Positive-business-momentum-despite-COVID-19-impact
While stepping up its investments in R&D significantly, Boehringer Ingelheim achieved a solid business performance in 2020 despite the COVID-19 pandemic.
Search
Cardiometabolic Diseases
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in CardioMetabolic diseases.
Collaboration to fight NCDs
70 percent of global deaths are attributable to NCDs and severely impacting on people in low- and middle-income countries. Help is desperately needed.
More Green Overview
Our pillar MORE GREEN encompasses environmental initiatives that consider many different aspects.
FreVAX smartphone application piglet vaccination
New FreVAX™ smartphone application brings piglet vaccination to another level
Fast-Track-Designation-NASH
Boehringer Ingelheim and Zealand Pharma announced that the FDA granted Fast Track Designation to the dual agonist BI 456906 for adults with NASH.
Human Health
Human Health
Scleroderma Life Hacks
Video series featuring people living with scleroderma using everyday items in different ways to help them manage their symptoms. Part of the global 'More Than Scleroderma' initiative developed by Boehringer Ingelheim, with support from patient organi
Resizing our Carbon Footprint
The ecological balance of the world is at a tipping point.
European Commission decision for Pradaxa® in children with VTE
Pradaxa® (dabigatran etexilate) receives EU marketing authorization for the treatment and prevention of VTE in children from birth to less than 18 years of age
Vaccines
Vaccines
Advances in vectored vaccines for poultry
Vaccine design technologies have made huge advances in recent years. One of the newer categories of vaccine, vectored vaccines, is overcoming challenges that conventional vaccines do not meet.
Moving towards a rabies-free Southeast Asia
Boehringer Ingelheim, in collaboration with Eco-Business, has published a comprehensive whitepaper to stop rabies.
collaboration-kings-college-london
Boehringer Ingelheim and the IoPPN at King’s College London partner to progress new therapeutic concepts in major depressive disorder and schizophrenia
Better Access to Healthcare for Indigenous Peoples
Indigenous Peoples often experience poor access to health care. Our initiatives from Canada and New Zealand aim to overcome the gap.
Production Insights
Boehringer Ingelheim makes an important contribution to the reliable and sustainable supply of pharmaceuticals
Corporate Profile
Corporate Profile
Biberach
The largest research and development center of Boehringer Ingelheim is located in Biberach, Germany.
Supporting local communities by offsetting carbon emissions
Boehringer Ingelheim partially offsets its carbon emissions by partnering with ClimateSeed
2021 ABCD Young Scientist Award feline health
Young veterinary researchers Julia Klaus and Dr Yasmin Parr receive award for their work into feline SARS-CoV-2 infections and feline leukaemia virus.
Rabies prevention local action partnering organizations
Global rabies prevention needs local action. Together with partnering organizations, we’re using pilot projects to find the right approach.
Mental Disorders
Mental Disorders
Saving Stroke Patients around the world
Suffering a stroke is one of the most devastating medical emergencies that can happen to a person. Over 15 million people worldwide suffer a stroke every year.
About Us
About us
2019 performance
Global Support Program addresses COVID-19 crisis with relief fund initiatives and volunteering support, donations, and concrete research activities.